{"gene":"CYP11B2","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1989,"finding":"CYP11B2 was identified as a second human steroid 11β-hydroxylase gene (alongside CYP11B1), each containing nine exons. The CYP11B2-encoded protein shares 93% amino acid identity with CYP11B1, but the 5'-flanking regions of the two genes diverge considerably, and CYP11B2 transcripts were not detected in normal adrenal mRNA at the time of initial characterization.","method":"Genomic cloning, sequencing, exon-intron mapping, and comparative analysis of CYP11B1 and CYP11B2 genes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — foundational cloning and sequencing study, highly cited, establishes gene structure","pmids":["2592361"],"is_preprint":false},{"year":1990,"finding":"The CYP11B2-encoded protein (P-450aldo) was shown by cDNA expression in COS-7 cells to preferentially catalyze the full conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone, whereas the closely related P-450(11)β (CYP11B1 product) substantially fails to catalyze aldosterone formation, establishing CYP11B2 as the aldosterone synthase.","method":"cDNA cloning from adrenal tumor, expression in COS-7 cells, steroid product analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution in heterologous cells, directly demonstrates enzymatic distinction between paralogs","pmids":["2256920"],"is_preprint":false},{"year":1991,"finding":"Expression of CYP11B2 cDNA in COS-1 cells demonstrated that its protein product can 11β-hydroxylate, 18-hydroxylate, and 18-oxidize corticosteroids, synthesizing aldosterone from deoxycorticosterone, whereas CYP11B1 product only 11β-hydroxylates. CYP11B2 mRNA is induced in adrenal zona glomerulosa cells by angiotensin II, confirming CYP11B2 is required for aldosterone biosynthesis.","method":"PCR-based expression analysis, cDNA cloning, transient transfection of COS-1 cells, steroid product measurement","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 — functional reconstitution in heterologous cells with product analysis, replicated across normal and tumor tissue","pmids":["1775135"],"is_preprint":false},{"year":1992,"finding":"CYP11B2 encodes both steroid 11β-hydroxylase and 18-hydroxylase (P-450C18/aldosterone synthase) activities. Expression in COS-7 cells confirmed that CYP11B2 product catalyzes synthesis of aldosterone and 18-oxocortisol, whereas CYP11B1 product exclusively exhibits 11β-hydroxylase activity. Promoter deletion analysis showed the two genes are regulated by distinct transcriptional mechanisms.","method":"Genomic cloning, cDNA expression in COS-7 cells, CAT reporter gene assays with deletion mutants of promoter regions in Y-1 adrenal tumor cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — enzymatic reconstitution plus promoter functional analysis, independently consistent with other expression studies","pmids":["1741400"],"is_preprint":false},{"year":1992,"finding":"Glucocorticoid-suppressible hyperaldosteronism (GSH) is caused by unequal meiotic crossing-over between CYP11B1 and CYP11B2, generating a hybrid gene with CYP11B1 5'-regulatory/coding sequences and CYP11B2 3'-coding sequences. Cells transfected with hybrid cDNAs containing up to three CYP11B1 exons synthesized aldosterone at near-normal levels, but hybrids with five or more CYP11B1 exons could not produce detectable aldosterone, mapping the aldosterone synthase functional determinants to the 3' coding region of CYP11B2.","method":"Southern blot, PCR detection of hybrid genes in patients, transient transfection of hybrid cDNAs in cultured cells with steroid product measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — functional reconstitution with mutagenesis (exon swapping), mechanistically maps aldosterone synthase activity to CYP11B2 coding sequences","pmids":["1518866"],"is_preprint":false},{"year":1992,"finding":"Glucocorticoid-remediable aldosteronism in 12 kindreds is caused by chimeric gene duplications fusing CYP11B1 regulatory sequences to CYP11B2 coding sequences via unequal crossing-over at introns 2–4, placing aldosterone synthase under ACTH/glucocorticoid-suppressible regulation. Sites of crossing-over range from intron 2 to intron 4.","method":"Southern blot and PCR analysis of chimeric gene structure in affected kindreds","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic mechanism established in 12 independent kindreds, consistent with biochemical phenotype","pmids":["1303253"],"is_preprint":false},{"year":1992,"finding":"Two point mutations in CYP11B2 — R181W (exon 3) and V386A (exon 7) — were identified as the molecular basis of corticosterone methyloxidase II (CMO-II) deficiency. When expressed in cultured cells, R181W abolished 18-oxidase activity and reduced 18-hydroxylase activity while preserving 11β-hydroxylase activity; V386A caused a smaller reduction in 18-hydroxycorticosterone production. These mutations map the 18-oxidase and 18-hydroxylase functions to specific CYP11B2 residues.","method":"Mutation identification by sequencing, site-directed mutagenesis of CYP11B2 cDNA, expression in cultured cells with steroid product assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional reconstitution in cells, activity mapped to specific residues","pmids":["1594605"],"is_preprint":false},{"year":1992,"finding":"Point mutations R181W and V386A in CYP11B2 (P-450C18) were confirmed in CMO-II deficiency patients by PCR-restriction analysis, with patients homozygous for both mutations and unaffected parents heterozygous, consistent with autosomal recessive inheritance.","method":"PCR-restriction enzyme analysis of CYP11B2 mutations in patients and family members","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — independent confirmation of disease-causing mutations in CYP11B2","pmids":["1346492"],"is_preprint":false},{"year":1991,"finding":"Rat cytochrome P-450aldo (CYP11B2 ortholog) and P-450(11)β genes share similar intron-exon organization but have divergent 5'-flanking regions. A putative cAMP-responsive element (TGACGTGA) is present in the P-450aldo gene but altered in P-450(11)β, suggesting differential transcriptional regulation. S1 nuclease assay identified a single transcription initiation site for P-450aldo.","method":"Genomic cloning, sequencing, S1 nuclease protection assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 structural data (sequencing, S1 mapping) but in rat ortholog, single lab","pmids":["1953771"],"is_preprint":false},{"year":1995,"finding":"A mutation T318M in CYP11B2 was identified in a patient with CMO-II deficiency. When this mutation (along with parental allele mutations R181W, delta C372, and V386A) was expressed in cDNA vectors, neither allele contributed measurable aldosterone synthase activity, yet the clinical phenotype was CMO-II (not CMO-I), suggesting that factors beyond CYP11B2 enzymatic activity modulate the severity of the deficiency phenotype.","method":"Direct DNA sequencing, cDNA expression in cultured cells with steroid assay","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 — mutagenesis and expression, but interpretation complicated by genotype-phenotype discordance","pmids":["7485152"],"is_preprint":false},{"year":1996,"finding":"A gene conversion in exons 3-4 of CYP11B2 (introducing D141E, K151N, I246T changes) was identified in CMO-II deficiency patients, but functional expression in COS-1, MA-10, and JEG-3 cells showed that these triple mutations retain normal 18-oxidase activity, demonstrating the gene conversion per se does not cause CMO-II deficiency and pointing to unidentified mutations elsewhere.","method":"Sequencing of CYP11B2, site-directed mutagenesis, expression in COS-1, MA-10, and JEG-3 cells, steroid product assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — thorough mutagenesis (7 constructs) with functional assay in multiple cell lines","pmids":["8550772"],"is_preprint":false},{"year":1996,"finding":"Calcium signaling via L-type calcium channel activation and ionomycin treatment increases human CYP11B2 reporter gene expression in H295R adrenocortical cells but not in Y-1 cells, demonstrating that calcium-signaling pathways regulate CYP11B2 transcription, and that H295R is the appropriate model for this study.","method":"Transient transfection of luciferase reporter constructs containing CYP11B2 5'-flanking DNA in H295R and Y-1 adrenocortical cell lines","journal":"Endocrine research","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay with pharmacological interventions in relevant cell line, single lab","pmids":["8969900"],"is_preprint":false},{"year":1997,"finding":"Angiotensin II, K+, and cAMP signaling pathways regulate human CYP11B2 transcription through two distinct cis-elements: a CRE-like element at -71/-64 (TGACGTGA) that binds CREB proteins, and an SF-1/COUP-TF binding element at -129/-114. Both elements are required for full basal activity and maximal induction, as shown by deletion, mutation, DNase I footprinting, and EMSA analyses.","method":"Transient transfection of deletion/mutation reporter constructs in H295R cells, DNase I footprinting, EMSA with nuclear extracts","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (footprinting, EMSA, deletion/mutation reporters), identifies specific cis-elements and binding proteins","pmids":["9139807"],"is_preprint":false},{"year":1997,"finding":"Angiotensin II and KCl stimulate CYP11B2 promoter activity in NCI-H295 cells via common cis-elements. A cis-element at -143/-161 is required for high-level promoter activity upon stimulation. Calcium channel blockade abolishes KCl stimulation, while protein kinase C inhibition (bisindolylmaleimide) enhances promoter activity, indicating PKC negatively regulates CYP11B2 transcription, and the PKA pathway positively regulates it.","method":"Transient transfection of hamster CYP11B2 deletion/mutation reporter constructs in NCI-H295 cells, pharmacological inhibitors of calcium channels and PKC","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assays with pharmacological dissection, hamster ortholog in human cell line","pmids":["9584833"],"is_preprint":false},{"year":1998,"finding":"Two mutations E198D and V386A in CYP11B2 together cause aldosterone synthase deficiency type I in two twins. When expressed individually, these and R173K have modest effects; together, they cause decreased 11β-hydroxylase activity, large decrease of 18-hydroxylase, and absent 18-oxidase activity, demonstrating that combined mutations can produce a more severe phenotype than either alone.","method":"Sequencing of CYP11B2, transfection assays of mutant cDNA combinations in cultured cells with steroid product measurement","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with functional reconstitution, individually and in combination","pmids":["9814506"],"is_preprint":false},{"year":1998,"finding":"Rat CYP11B2 and the mutant DR-CYP11B1 (from Dahl salt-resistant rats) were expressed in Escherichia coli. The V381L and I384L double mutation in CYP11B1 accounts for its low 18-hydroxylase activity. V443M is responsible for decreased 19-hydroxylase activity. These results functionally assign 18-hydroxylase and 19-hydroxylase activities to specific residues in the CYP11B sequence.","method":"Site-directed mutagenesis, expression of rat CYP11B1 and CYP11B2 in E. coli, in vitro steroid hydroxylation assays","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with site-directed mutagenesis maps specific activities to residues","pmids":["9874258"],"is_preprint":false},{"year":2000,"finding":"The CRE/Ad1 cis-element is required for basal expression and agonist-stimulated transcription of both CYP11B1 and CYP11B2, but mutation of the CRE in CYP11B2 abolishes basal expression yet retains agonist (angiotensin II, cAMP) response, suggesting additional cis-elements mediate hormonal regulation of CYP11B2. EMSA demonstrated binding of CREB, ATF-1, and ATF-2 to the CRE elements, with ATF-2 forming the complex most similar to that seen in H295R nuclear extracts.","method":"Transient transfection of CYP11B1 and CYP11B2 reporter constructs with CRE mutations in H295R cells, EMSA with in vitro transcription factor proteins and nuclear extracts","journal":"Endocrine research","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of cis-element combined with EMSA identifies transcription factor binding","pmids":["11196473"],"is_preprint":false},{"year":2002,"finding":"Steroidogenic factor-1 (SF-1) paradoxically inhibits CYP11B2 reporter activity while stimulating CYP11B1, CYP11A1, and CYP17 reporters, making CYP11B2 the first steroid hydroxylase not positively regulated by SF-1. The -344C/T polymorphism in the Ad4 (SF-1 binding) element of CYP11B2 influences SF-1 binding in EMSA (C allele binds more strongly), but does not alter agonist-stimulated reporter expression in H295R cells.","method":"Transient co-transfection of reporter constructs with SF-1 expression vectors in H295R and Y-1 cells, EMSA with SF-1 and -344C/T allele probes","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 — functional reconstitution with multiple reporters and EMSA, distinguishes SF-1 regulation of paralogs","pmids":["11932209"],"is_preprint":false},{"year":2002,"finding":"Calmodulin-dependent kinase I (CaMKI) is the primary calcium-dependent kinase regulating CYP11B2 transcription. Constitutively active CaMKI stimulated CYP11B2 reporter expression in H295R cells via the cAMP regulatory element at -71/-64, while CaMKII had no effect and CaMKIV had a small effect. CaMKI expression was confirmed in adrenal cortex and H295R cells by immunohistochemistry and Western/Northern blot.","method":"Transient transfection of CaMK expression vectors and CYP11B2 reporter constructs in H295R cells, pharmacological inhibitors (KN93, calmidazolium), mutational analysis of promoter, immunohistochemistry, Western and Northern blot","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods identifying CaMKI as the specific kinase, with promoter mutagenesis linking it to a defined cis-element","pmids":["12193581"],"is_preprint":false},{"year":2002,"finding":"The amino acid substitutions I112P and D147E in human CYP11B2 increase 11β-hydroxylation activity (up to 6-fold when combined), while I112P enhances 18-hydroxylase activity by 70%. The 18-oxidase activity is slightly reduced by most mutations except D147E. Residue I112 in the putative substrate access channel and D147 on the protein surface influence substrate recognition and conversion in CYP11B2.","method":"Site-directed mutagenesis of CYP11B2 residues, expression of mutant proteins in E. coli, in vitro steroid hydroxylation assays, computer homology modeling","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro mutagenesis with enzymatic assay maps specific residues to reaction steps","pmids":["11856349"],"is_preprint":false},{"year":2002,"finding":"Human CYP11B2 was functionally expressed in fission yeast (Schizosaccharomyces pombe), where its mitochondrial targeting signal is functional (confirmed by Western blot, fluorescence, and electron microscopy). A novel fission yeast ferredoxin-domain protein, etp1, can replace adrenodoxin in electron transfer to CYP11B2, enabling steroid hydroxylation in a reconstituted assay. CYP11B2 in intact yeast cells converts 11-deoxycorticosterone to corticosterone, 18-hydroxycorticosterone, and aldosterone.","method":"Heterologous expression in S. pombe, Western blot, fluorescence and electron microscopy for localization, in vivo and reconstituted in vitro steroid hydroxylation assays with recombinant etp1","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with multiple orthogonal localization methods, identifies novel electron transfer partner etp1","pmids":["11841224"],"is_preprint":false},{"year":2006,"finding":"PCB126 upregulates CYP11B2 mRNA in H295R human adrenocortical cells not through aryl hydrocarbon receptor (AhR)-mediated transcriptional activation, but by increasing posttranscriptional mRNA stability, as demonstrated by AhR antagonist experiments (which failed to block induction) and RNA degradation assays. An internal region of CYP11B1 mRNA (nucleotides 881-1285) was identified as important for PCB126-mediated transcript stabilization.","method":"AhR antagonist (3',4'-DMF) treatment, RNA degradation assays, promoter analyses, RT-PCR in H295R cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection and RNA stability assay in relevant cell line, single lab","pmids":["16396990"],"is_preprint":false},{"year":2001,"finding":"A deletion hybrid CYP11B gene (CYP11B2 promoter + exons 1-6 fused to CYP11B1 exons 7-9 plus an I339T intracodon mutation) was characterized in a patient with 11β-hydroxylase deficiency/congenital adrenal hyperplasia. Expression of the corresponding cDNA in COS-1 cells showed relatively unimpaired 11β-hydroxylase and aldosterone synthase activities, demonstrating that the 11β-hydroxylase deficiency results from absence of CYP11B1 zona fasciculata expression rather than enzymatic incapacity.","method":"Gene structure determination, cDNA expression in COS-1 cells, steroid product assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 — reconstitution in COS-1 cells, but single patient/case","pmids":["11443188"],"is_preprint":false},{"year":2011,"finding":"CYP11B2 promoter activity is regulated by Alu retrotransposable elements (functioning as enhancers) and conserved proximal cis-elements including Ad5 (bound by ERRα during basal expression) and SF-1 sites. Mutation of the Ad5 site reduces promoter activity to minimal levels. CYP11B1-specific L1 element (CYP11B1-L1.2) inserted between Alu and the conserved region blocks Alu enhancement in CYP11B1 but not CYP11B2, explaining part of the differential regulation of the two paralogs.","method":"Reporter gene assays with deletion/mutation constructs, EMSA, sequence analysis, transposable element functional dissection in adrenocortical cell lines","journal":"Steroids","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter dissection with EMSA, identifies ERRα as Ad5 binding transcription factor","pmids":["22079243"],"is_preprint":false},{"year":2013,"finding":"Crystal structures of human aldosterone synthase (CYP11B2) in complex with substrate deoxycorticosterone and inhibitor fadrozole were solved. The structures reveal a hydrophobic active site with features for corticosteroid recognition. Divergent residues conferring 18-oxidase activity (unique to CYP11B2 vs. CYP11B1) are located in the I-helix (near O2 activation) and loops around the H-helix (affecting an egress channel required for retaining intermediates). Fadrozole binds in R-configuration using part of the active site cavity. Low processivity (high release of intermediates) is identified as a mechanism of controlled aldosterone production.","method":"X-ray crystallography of CYP11B2 with substrate and inhibitor, biochemical substrate conversion assays","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with biochemical validation, provides atomic-level mechanism for substrate specificity and catalysis","pmids":["23322723"],"is_preprint":false},{"year":2010,"finding":"Five novel CYP11B2 mutations causing aldosterone synthase deficiency type I (W260X, G206WfsX51, L496SfsX169, S315R, R374W) were identified. Expression of S315R and R374W in COS-1 cells showed complete absence of CYP11B2 activity for conversion of 11-deoxycorticosterone to aldosterone. 3D modeling indicated these mutations disrupt hydrogen bond networks in the enzyme.","method":"Sequencing, expression of mutant CYP11B2 in COS-1 cells, steroid product assay, 3D structural modeling","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 1 — functional expression with activity assay for multiple mutants, structural modeling support","pmids":["20494601"],"is_preprint":false},{"year":2008,"finding":"A novel CYP11B2 mutation S308P (T925C in exon 5) was identified in siblings with hyperreninemic hypoaldosteronism. Functional characterization in vitro showed complete loss of enzyme activity. Structural modeling placed S308 within the alpha-helix I near the heme-binding active site. However, in vivo dexamethasone treatment further reduced aldosterone levels, suggesting some residual mineralocorticoid biosynthesis occurs through alternative pathways or residual mutant activity.","method":"Sequencing, in vitro functional expression of S308P mutant, structural modeling, dexamethasone suppression test in vivo","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with structural modeling localizes mutation to active site; in vivo test provides additional context","pmids":["19116236"],"is_preprint":false},{"year":2011,"finding":"HDL2 stimulates aldosterone synthesis in H295R human adrenocortical cells by increasing CYP11B2 mRNA expression up to 19-fold. This effect is mediated through a calcium signaling cascade (abolished by calcium channel blockers and calmodulin kinase inhibitors) and is not additive with angiotensin II or K+ stimulation.","method":"H295R cell treatment with HDL subfractions, CYP11B2 mRNA quantification, aldosterone measurement, pharmacological inhibitors of calcium signaling","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with dose-response and time-course data, single lab","pmids":["21239432"],"is_preprint":false},{"year":2014,"finding":"miR-10b, induced by hypoxia and HIF-1α in H295R adrenocortical cells, negatively regulates CYP11B2 (and CYP11B1) mRNA through their 3'-UTRs. Luciferase assays with 3'-UTR constructs, combined with miRNA overexpression and knockdown, established CYP11B2 as a direct post-transcriptional target of miR-10b.","method":"miRNA arrays, luciferase reporter assays with CYP11B2 3'-UTR in H295R cells, miRNA overexpression and knockdown, HIF-1α overexpression","journal":"Marine pollution bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter and miRNA gain/loss-of-function establish direct post-transcriptional regulation","pmids":["24768260"],"is_preprint":false},{"year":2015,"finding":"Torasemide (but not furosemide) inhibits human CYP11B2 enzymatic activity by 75% in transfected lung fibroblasts (V79MZ cells), independently of mineralocorticoid receptor. In mice with cardiac Rac1 overexpression, torasemide prevented atrial fibrosis and atrial fibrillation correlated with suppression of CTGF, LOX, and miR-21; the selective CYP11B2 inhibitor SL242 mimicked torasemide effects, establishing CYP11B2 activity as a contributor to atrial fibrosis.","method":"CYP11B2 activity assay in transfected cells, cardiac fibroblast assays, in vivo mouse model with torasemide/furosemide treatment, gene expression and histology","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro enzyme assay plus in vivo model with specific inhibitor control, single lab","pmids":["26047574"],"is_preprint":false},{"year":2018,"finding":"miR-193a-3p directly targets the 3'-UTR of CYP11B2 in H295R adrenocortical cells, as validated by luciferase reporter assay and site-directed mutation of the binding site. Overexpression of miR-193a-3p reduces CYP11B2 mRNA and protein, decreases aldosterone secretion, inhibits proliferation, and promotes apoptosis. Restoration of CYP11B2 rescues these effects, establishing CYP11B2 as a functional target of miR-193a-3p in aldosterone-producing adenoma.","method":"Luciferase reporter assays with wild-type and mutant CYP11B2 3'-UTR, miRNA mimic transfection in H295R cells, qRT-PCR, Western blot, aldosterone ELISA, flow cytometry","journal":"International journal of experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter with mutation confirms direct target, functional rescue experiment adds specificity","pmids":["29665181"],"is_preprint":false},{"year":2021,"finding":"Atractylenolide-I (AT-I) selectively inhibits CYP11B2 through a covalent mechanism: the C8/C9 double bond of AT-I is epoxidized and then undergoes nucleophilic addition with Cys450 of CYP11B2 (enabled by the presence of Ala320 in CYP11B2, absent in CYP11B1). This covalent binding disrupts the interaction between heme and CYP11B2, inactivating the enzyme and suppressing aldosterone synthesis without affecting CYP11B1-mediated cortisol production.","method":"Chemical biology/activity-based protein profiling, molecular docking, mutagenesis, cell-based aldosterone/cortisol measurement, in vivo hyperaldosteronism model","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — covalent binding mechanism characterized by chemical biology and structural modeling with functional validation, single lab","pmids":["35127376"],"is_preprint":false},{"year":2023,"finding":"DNA methylation negatively controls CYP11B2 expression; hypomethylation of the CYP11B2 promoter is seen in aldosterone-producing adenomas. Methylation of recognition sites for CREB1 and NGFIB (nerve growth factor-induced clone B) reduces their DNA-binding activity. Methyl-CpG-binding protein 2 (MeCP2) directly cooperates with methylated CpG dinucleotides of the CYP11B2 promoter. Low-salt diet, angiotensin II, and K+ stimulation increase CYP11B2 mRNA and induce promoter DNA hypomethylation.","method":"DNA methylation array, bisulfite sequencing, reporter assays, EMSA, adrenal tissue analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic epigenetic regulation supported by multiple methods and tissue data","pmids":["36982850"],"is_preprint":false}],"current_model":"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 enzyme that catalyzes the final three steps of aldosterone biosynthesis—11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone—with distinct active-site features (I-helix near O2 activation, H-helix egress channel loops, and Cys450) that confer its unique 18-oxidase activity compared to the paralogous CYP11B1; its transcription in adrenal zona glomerulosa is activated by angiotensin II and K+ via calcium/CaMKI signaling and cAMP pathways converging on a CRE-like element and an SF-1/COUP-TF site in its promoter, is paradoxically inhibited (not activated) by SF-1, and is negatively regulated post-transcriptionally by miR-10b, miR-193a-3p, and epigenetically by promoter DNA methylation through MeCP2 and CREB/NGFIB binding site methylation."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of CYP11B2 as a second 11β-hydroxylase gene with divergent promoter architecture established that aldosterone biosynthesis could be genetically separable from cortisol production.","evidence":"Genomic cloning and sequencing of the human CYP11B locus revealed two nine-exon genes sharing 93% protein identity but with divergent 5′-flanking regions.","pmids":["2592361"],"confidence":"High","gaps":["CYP11B2 transcripts were not detectable in normal adrenal at time of cloning","enzymatic activity not yet assigned to the CYP11B2 product"]},{"year":1990,"claim":"Functional reconstitution answered whether CYP11B2 encodes a distinct enzyme: its product catalyzes the complete conversion of deoxycorticosterone to aldosterone, while CYP11B1 cannot, establishing CYP11B2 as aldosterone synthase.","evidence":"cDNA expression in COS-7 and COS-1 cells with steroid product analysis demonstrated 11β-hydroxylase, 18-hydroxylase, and 18-oxidase activities for CYP11B2 but only 11β-hydroxylase for CYP11B1.","pmids":["2256920","1775135","1741400"],"confidence":"High","gaps":["structural basis for 18-oxidase specificity not determined","electron transfer partners not defined"]},{"year":1992,"claim":"Genetic studies resolved the molecular basis of two Mendelian disorders: loss-of-function CYP11B2 mutations (R181W, V386A) cause corticosterone methyloxidase II deficiency, while chimeric CYP11B1/CYP11B2 genes from unequal crossing-over cause glucocorticoid-remediable aldosteronism, mapping disease-critical 18-oxidase determinants to the 3′ coding region.","evidence":"Patient sequencing, exon-swap constructs expressed in cultured cells, and Southern blot/PCR of chimeric genes across 12 kindreds.","pmids":["1594605","1346492","1518866","1303253"],"confidence":"High","gaps":["genotype-phenotype discordance (CMO-I vs CMO-II) not fully explained by in vitro activity","additional unidentified mutations or modifiers suggested by some pedigrees"]},{"year":1997,"claim":"Promoter dissection identified the cis-regulatory logic of CYP11B2: a CRE-like element at −71/−64 binding CREB/ATF factors and an SF-1/COUP-TF element at −129/−114 are both required for basal activity and agonist (angiotensin II, K⁺, cAMP) induction.","evidence":"Deletion/mutation reporter constructs, DNase I footprinting, and EMSA with H295R adrenocortical cell nuclear extracts.","pmids":["9139807","9584833"],"confidence":"High","gaps":["identity of trans-acting factors mediating agonist-specific responses not fully resolved","role of distal enhancers (e.g., Alu elements) not yet explored"]},{"year":2002,"claim":"The calcium/calmodulin-dependent kinase CaMKI was identified as the specific kinase transducing calcium signals to CYP11B2 transcription via the CRE element, while SF-1 was shown to paradoxically repress CYP11B2—making it unique among steroidogenic genes.","evidence":"Constitutively active CaMK isoform transfections with CYP11B2 reporter and CRE mutations in H295R cells; SF-1 co-transfection assays comparing CYP11B2 with CYP11B1/CYP11A1/CYP17 reporters.","pmids":["12193581","11932209"],"confidence":"High","gaps":["downstream transcription factor phosphorylated by CaMKI not identified","mechanism of SF-1 repression unknown"]},{"year":2002,"claim":"Site-directed mutagenesis of specific residues (I112, D147, V381, I384) mapped substrate access and individual catalytic steps (11β-hydroxylation, 18-hydroxylation, 18-oxidation) to discrete structural features, advancing understanding of how CYP11B2 differs from CYP11B1 at the atomic level.","evidence":"Mutant CYP11B2 and CYP11B1 proteins expressed in E. coli with in vitro steroid hydroxylation assays and homology modeling.","pmids":["11856349","9874258"],"confidence":"High","gaps":["no experimental 3D structure available at this time","electron transfer coupling not structurally characterized"]},{"year":2013,"claim":"Crystal structures of CYP11B2 with substrate (deoxycorticosterone) and inhibitor (fadrozole) revealed the structural basis of 18-oxidase specificity: divergent I-helix residues near the O₂ activation site and H-helix egress-channel loops retain reaction intermediates, while low processivity limits aldosterone output.","evidence":"X-ray crystallography at atomic resolution combined with biochemical substrate conversion assays.","pmids":["23322723"],"confidence":"High","gaps":["no structure of CYP11B2 bound to 18-hydroxycorticosterone intermediate","dynamic conformational changes during catalytic cycle not captured"]},{"year":2014,"claim":"Post-transcriptional regulation of CYP11B2 was established: miR-10b and later miR-193a-3p directly target the CYP11B2 3′-UTR, adding a layer of negative regulation beyond transcriptional control.","evidence":"Luciferase reporter assays with wild-type and mutant 3′-UTR constructs, miRNA overexpression/knockdown, and functional rescue in H295R cells.","pmids":["24768260","29665181"],"confidence":"Medium","gaps":["physiological contexts triggering miR-10b or miR-193a-3p regulation of aldosterone in vivo not established","relative contribution of miRNA versus transcriptional regulation to aldosterone output unknown"]},{"year":2021,"claim":"Chemical biology identified a covalent inhibition mechanism exploiting Cys450 and Ala320 unique to CYP11B2: atractylenolide-I is epoxidized and covalently modifies Cys450, disrupting heme interaction and selectively inactivating aldosterone synthase without affecting CYP11B1.","evidence":"Activity-based protein profiling, molecular docking, mutagenesis, and cell-based aldosterone/cortisol assays with in vivo hyperaldosteronism model.","pmids":["35127376"],"confidence":"Medium","gaps":["co-crystal structure of covalent adduct not obtained","pharmacokinetics and selectivity in humans unknown"]},{"year":2023,"claim":"Epigenetic regulation was defined: CYP11B2 promoter DNA methylation recruits MeCP2 and reduces CREB1/NGFIB binding, while physiological stimuli (low salt, angiotensin II, K⁺) induce promoter hypomethylation, linking environmental signals to epigenetic derepression.","evidence":"DNA methylation arrays, bisulfite sequencing, EMSA, and reporter assays in adrenal tissue and cell lines.","pmids":["36982850"],"confidence":"Medium","gaps":["identity of demethylase(s) mediating stimulus-dependent hypomethylation unknown","relative importance of methylation versus transcription factor availability in vivo not quantified"]},{"year":null,"claim":"The structural dynamics of CYP11B2 during the multi-step catalytic cycle—particularly how intermediates (corticosterone, 18-hydroxycorticosterone) are retained or released, and how electron transfer from adrenodoxin is coupled to each oxidation step—remain incompletely resolved at the structural level.","evidence":"","pmids":[],"confidence":"Medium","gaps":["no structures of intermediate-bound states","cryo-EM or time-resolved crystallography of catalytic cycle not performed","in vivo regulation of CYP11B2 processivity not characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[1,2,3,6,15,19,24,25]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[24]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[20,24]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,2,3,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,18,27]}],"complexes":[],"partners":["CYP11B1","SF1","CREB1","ATF2","CAMK1","MECP2"],"other_free_text":[]},"mechanistic_narrative":"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 that catalyzes the final three steps of aldosterone biosynthesis—11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone—activities that distinguish it from its 93%-identical paralog CYP11B1, which lacks 18-oxidase capacity [PMID:2256920, PMID:23322723]. Crystal structures reveal that the unique 18-oxidase activity depends on divergent residues in the I-helix near the oxygen activation site and loops around the H-helix that form an egress channel retaining intermediates, with low processivity controlling aldosterone output [PMID:23322723]. Transcription in the adrenal zona glomerulosa is driven by angiotensin II and K⁺ via calcium/CaMKI signaling converging on a CRE-like element (−71/−64) and an SF-1/COUP-TF site, with SF-1 paradoxically repressing CYP11B2 while activating other steroidogenic genes [PMID:9139807, PMID:12193581, PMID:11932209]. Loss-of-function mutations cause corticosterone methyloxidase deficiency (types I and II), while chimeric CYP11B1/CYP11B2 genes arising from unequal crossing-over cause glucocorticoid-remediable aldosteronism [PMID:1594605, PMID:1303253]."},"prefetch_data":{"uniprot":{"accession":"P19099","full_name":"Cytochrome P450 11B2, mitochondrial","aliases":["Aldosterone synthase","ALDOS","Aldosterone-synthesizing enzyme","CYPXIB2","Corticosterone 18-monooxygenase, CYP11B2","Cytochrome P-450Aldo","Cytochrome P-450C18","Steroid 11-beta-hydroxylase, CYP11B2","Steroid 18-hydroxylase"],"length_aa":503,"mass_kda":57.6,"function":"A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:15356073, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814482, PubMed:9814506). Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two successive oxidations at C18 yielding 18-hydroxy and then 18-oxo intermediates (that would not leave the enzyme active site during the consecutive hydroxylation reactions), ending with the formation of aldosterone (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814506). Can also produce 18-hydroxycortisol and 18-oxocortisol, derived from successive oxidations of cortisol at C18, normally found at very low levels, but significantly increased in primary aldosteronism, the most common form of secondary hypertension (PubMed:15356073, PubMed:9814482). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:11856349, PubMed:1594605, PubMed:23322723, PubMed:9814506). Could also be involved in the androgen metabolic pathway (Probable)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P19099/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP11B2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP11B2","total_profiled":1310},"omim":[{"mim_id":"617027","title":"HYPERALDOSTERONISM, FAMILIAL, TYPE IV; HALD4","url":"https://www.omim.org/entry/617027"},{"mim_id":"613815","title":"CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2","url":"https://www.omim.org/entry/613815"},{"mim_id":"613677","title":"HYPERALDOSTERONISM, FAMILIAL, TYPE III; HALD3","url":"https://www.omim.org/entry/613677"},{"mim_id":"610613","title":"CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 1; CYP11B1","url":"https://www.omim.org/entry/610613"},{"mim_id":"610600","title":"CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY","url":"https://www.omim.org/entry/610600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"adrenal gland","ntpm":178.8}],"url":"https://www.proteinatlas.org/search/CYP11B2"},"hgnc":{"alias_symbol":["CYP11BL","CPN2","P-450C18","P450aldo","ALDOS"],"prev_symbol":["CYP11B"]},"alphafold":{"accession":"P19099","domains":[{"cath_id":"1.10.630.10","chopping":"39-502","consensus_level":"medium","plddt":93.5718,"start":39,"end":502}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19099","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19099-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19099-F1-predicted_aligned_error_v6.png","plddt_mean":89.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP11B2","jax_strain_url":"https://www.jax.org/strain/search?query=CYP11B2"},"sequence":{"accession":"P19099","fasta_url":"https://rest.uniprot.org/uniprotkb/P19099.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19099/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19099"}},"corpus_meta":[{"pmid":"1775135","id":"PMC_1775135","title":"The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex.","date":"1991","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1775135","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24325867","id":"PMC_24325867","title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24325867","citation_count":245,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1518866","id":"PMC_1518866","title":"Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1518866","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7588407","id":"PMC_7588407","title":"Haplotype analysis of CYP11B2.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588407","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9139807","id":"PMC_9139807","title":"Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements.","date":"1997","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9139807","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2256920","id":"PMC_2256920","title":"Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism.","date":"1990","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2256920","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1594605","id":"PMC_1594605","title":"Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1594605","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9931115","id":"PMC_9931115","title":"Genetic polymorphism of CYP11B2 gene and hypertension in Japanese.","date":"1999","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/9931115","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23443813","id":"PMC_23443813","title":"Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23443813","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27872236","id":"PMC_27872236","title":"Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).","date":"2016","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27872236","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10720581","id":"PMC_10720581","title":"Lys(173)Arg and -344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10720581","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9506770","id":"PMC_9506770","title":"Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9506770","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9814506","id":"PMC_9814506","title":"Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9814506","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9745430","id":"PMC_9745430","title":"Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9745430","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15361760","id":"PMC_15361760","title":"Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population.","date":"2004","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15361760","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11914098","id":"PMC_11914098","title":"Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.","date":"2002","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11914098","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12457455","id":"PMC_12457455","title":"Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas.","date":"2002","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12457455","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16220979","id":"PMC_16220979","title":"Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16220979","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12817181","id":"PMC_12817181","title":"Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension.","date":"2003","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/12817181","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26756116","id":"PMC_26756116","title":"A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism.","date":"2016","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26756116","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11725161","id":"PMC_11725161","title":"Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study.","date":"2001","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/11725161","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8550772","id":"PMC_8550772","title":"Gene conversion in the CYP11B2 gene encoding P450c11AS is associated with, but does not cause, the syndrome of corticosterone methyloxidase II deficiency.","date":"1996","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8550772","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14736447","id":"PMC_14736447","title":"Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension.","date":"2004","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/14736447","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1346492","id":"PMC_1346492","title":"Congenitally defective aldosterone biosynthesis in humans: the involvement of point mutations of the P-450C18 gene (CYP11B2) in CMO II deficient patients.","date":"1992","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1346492","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10608469","id":"PMC_10608469","title":"Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST).","date":"1999","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/10608469","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7485152","id":"PMC_7485152","title":"Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7485152","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12788845","id":"PMC_12788845","title":"A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12788845","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12444540","id":"PMC_12444540","title":"Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension.","date":"2002","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/12444540","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10720582","id":"PMC_10720582","title":"Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10720582","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15545843","id":"PMC_15545843","title":"Multiple Polymorphisms in the renin- angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort.","date":"2004","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15545843","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16396990","id":"PMC_16396990","title":"Mechanistic study of polychlorinated biphenyl 126-induced CYP11B1 and CYP11B2 up-regulation.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16396990","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16179417","id":"PMC_16179417","title":"The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart.","date":"2005","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16179417","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17296872","id":"PMC_17296872","title":"Polymorphism of CYP11B2 determines salt sensitivity in Japanese.","date":"2007","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/17296872","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11443188","id":"PMC_11443188","title":"Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11443188","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24900631","id":"PMC_24900631","title":"Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.","date":"2013","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900631","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20598712","id":"PMC_20598712","title":"Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke.","date":"2010","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20598712","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11196473","id":"PMC_11196473","title":"Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element.","date":"2000","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/11196473","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29202495","id":"PMC_29202495","title":"Disordered CYP11B2 Expression in Primary Aldosteronism.","date":"2017","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/29202495","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15134824","id":"PMC_15134824","title":"The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15134824","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25102047","id":"PMC_25102047","title":"Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25102047","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15134825","id":"PMC_15134825","title":"Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15134825","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10577993","id":"PMC_10577993","title":"Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10577993","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26597777","id":"PMC_26597777","title":"Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26597777","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15238568","id":"PMC_15238568","title":"Genetic variation in CYP11B2 and AT1R influences heart rate variability conditional on sodium excretion.","date":"2004","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/15238568","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8969900","id":"PMC_8969900","title":"Calcium regulates human CYP11B2 transcription.","date":"1996","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/8969900","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1953771","id":"PMC_1953771","title":"Structural differences in 5'-flanking regions of rat cytochrome P-450aldo and P-450(11) beta genes.","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1953771","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7588405","id":"PMC_7588405","title":"Localization of P450aldo and P45011 beta in normal and regenerating rat adrenal cortex.","date":"1995","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/7588405","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15614025","id":"PMC_15614025","title":"Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion.","date":"2004","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15614025","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36982850","id":"PMC_36982850","title":"Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36982850","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27754862","id":"PMC_27754862","title":"Hypomethylation of CYP11B2 in Aldosterone-Producing Adenoma.","date":"2016","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27754862","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26047574","id":"PMC_26047574","title":"Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26047574","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24768260","id":"PMC_24768260","title":"Regulation of CYP11B1 and CYP11B2 steroidogenic genes by hypoxia-inducible miR-10b in H295R cells.","date":"2014","source":"Marine pollution bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/24768260","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9874258","id":"PMC_9874258","title":"Structure/function relationship of CYP11B1 associated with Dahl's salt-resistant rats--expression of rat CYP11B1 and CYP11B2 in Escherichia coli.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9874258","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21239432","id":"PMC_21239432","title":"Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2).","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21239432","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15643128","id":"PMC_15643128","title":"CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake.","date":"2005","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15643128","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19151144","id":"PMC_19151144","title":"High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome.","date":"2009","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/19151144","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16126185","id":"PMC_16126185","title":"Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China.","date":"2005","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16126185","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11600544","id":"PMC_11600544","title":"Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11600544","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9584833","id":"PMC_9584833","title":"Transcriptional activity of the hamster CYP11B2 promoter in NCI-H295 cells stimulated by angiotensin II, potassium, forskolin and bisindolylmaleimide.","date":"1998","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9584833","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15894890","id":"PMC_15894890","title":"Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2.","date":"2005","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15894890","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23150505","id":"PMC_23150505","title":"Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension.","date":"2012","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/23150505","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11245725","id":"PMC_11245725","title":"Aldosterone synthase (CYP11B2) gene polymorphism and cerebral white matter hyperintensities.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11245725","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10419019","id":"PMC_10419019","title":"Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function.","date":"1999","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10419019","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11422109","id":"PMC_11422109","title":"Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency.","date":"2001","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11422109","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15985365","id":"PMC_15985365","title":"The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.","date":"2005","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15985365","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11856349","id":"PMC_11856349","title":"The effect of amino-acid substitutions I112P, D147E and K152N in CYP11B2 on the catalytic activities of the enzyme.","date":"2002","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11856349","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32289837","id":"PMC_32289837","title":"Immunohistochemistry of the Human Adrenal CYP11B2 in Normal Individuals and in Patients with Primary Aldosteronism.","date":"2020","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/32289837","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16118341","id":"PMC_16118341","title":"Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16118341","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1423351","id":"PMC_1423351","title":"Synthesis of the antibiotic cortalcerone from D-glucose using pyranose 2-oxidase and a novel fungal enzyme, aldos-2-ulose dehydratase.","date":"1992","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/1423351","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35127376","id":"PMC_35127376","title":"Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35127376","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20494601","id":"PMC_20494601","title":"Five novel mutations in CYP11B2 gene detected in patients with aldosterone synthase deficiency type I: Functional characterization and structural analyses.","date":"2010","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20494601","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27853054","id":"PMC_27853054","title":"Expression of CYP11B2 in Aldosterone-Producing Adrenocortical Adenoma: Regulatory Mechanisms and Clinical Significance.","date":"2016","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27853054","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30058705","id":"PMC_30058705","title":"MiR-138-5p is downregulated in patients with atrial fibrillation and reverses cardiac fibrotic remodeling via repressing CYP11B2.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30058705","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20176774","id":"PMC_20176774","title":"Aldosterone synthase gene (CYP11B2) promoter polymorphism as a risk factor for ischaemic stroke in Tunisian Arabs.","date":"2010","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/20176774","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30561227","id":"PMC_30561227","title":"Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population.","date":"2018","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30561227","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11701710","id":"PMC_11701710","title":"Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11701710","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9029716","id":"PMC_9029716","title":"Expression of cytochromes P450aldo and P45011 beta in rat adrenal gland during late gestational and neonatal stages.","date":"1997","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/9029716","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19407459","id":"PMC_19407459","title":"Association between aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis.","date":"2009","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/19407459","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19117407","id":"PMC_19117407","title":"Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19117407","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24694176","id":"PMC_24694176","title":"The clinical significance of aldosterone synthase deficiency: report of a novel mutation in the CYP11B2 gene.","date":"2014","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/24694176","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17003099","id":"PMC_17003099","title":"CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17003099","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33682891","id":"PMC_33682891","title":"Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33682891","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29665181","id":"PMC_29665181","title":"MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2.","date":"2018","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29665181","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30974191","id":"PMC_30974191","title":"Expression of aldosterone synthase CYP11B2 was inversely correlated with longevity.","date":"2019","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30974191","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29630094","id":"PMC_29630094","title":"MiR-4421 regulates the progression of preeclampsia by regulating CYP11B2.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29630094","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32530624","id":"PMC_32530624","title":"Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32530624","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9408886","id":"PMC_9408886","title":"Expression of 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the human fetal adrenal.","date":"1997","source":"Journal of the Society for Gynecologic Investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9408886","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11422106","id":"PMC_11422106","title":"Polymorphic differences from normal in the aldosterone synthase gene (CYP11B2) in patients with primary hyperaldosteronism and adrenal tumour (Conn's syndrome).","date":"2001","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11422106","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34743356","id":"PMC_34743356","title":"Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism.","date":"2021","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34743356","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31302112","id":"PMC_31302112","title":"Analysis of novel heterozygous mutations in the CYP11B2 gene causing congenital aldosterone synthase deficiency and literature review.","date":"2019","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/31302112","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11146369","id":"PMC_11146369","title":"CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis.","date":"2000","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/11146369","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36036158","id":"PMC_36036158","title":"Changes of the CYP11B2 Expressing Zona Glomerulosa in Human Adrenals From Birth to 40 Years of Age.","date":"2022","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/36036158","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17762647","id":"PMC_17762647","title":"Skinfold thickness and blood pressure across C-344T polymorphism of CYP11B2 gene.","date":"2007","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/17762647","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26303746","id":"PMC_26303746","title":"Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26303746","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23135028","id":"PMC_23135028","title":"Association of CYP11B2 gene polymorphism with ischemic stroke in the north Chinese Han population.","date":"2012","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/23135028","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31096184","id":"PMC_31096184","title":"miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma.","date":"2019","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31096184","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19116236","id":"PMC_19116236","title":"A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19116236","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22079243","id":"PMC_22079243","title":"Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements.","date":"2011","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/22079243","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20339375","id":"PMC_20339375","title":"Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism.","date":"2010","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20339375","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26686590","id":"PMC_26686590","title":"Analysis of the gene polymorphism of aldosterone synthase (CYP11B2) and atrial natriuretic peptide (ANP) in women with preeclampsia.","date":"2015","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/26686590","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15583024","id":"PMC_15583024","title":"Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones.","date":"2004","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15583024","citation_count":1274,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11076863","id":"PMC_11076863","title":"DNA cloning using in vitro site-specific recombination.","date":"2000","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/11076863","citation_count":815,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391210","id":"PMC_10391210","title":"Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391210","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15128046","id":"PMC_15128046","title":"Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15128046","citation_count":729,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2592361","id":"PMC_2592361","title":"Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta).","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2592361","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28319085","id":"PMC_28319085","title":"Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.","date":"2017","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/28319085","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1303253","id":"PMC_1303253","title":"Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase.","date":"1992","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1303253","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1741400","id":"PMC_1741400","title":"Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1741400","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11518842","id":"PMC_11518842","title":"Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population.","date":"2001","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/11518842","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11711524","id":"PMC_11711524","title":"Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms.","date":"2001","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11711524","citation_count":149,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28566337","id":"PMC_28566337","title":"Age-Related Autonomous Aldosteronism.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28566337","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10902803","id":"PMC_10902803","title":"Steroidogenic enzyme gene expression in the human heart.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10902803","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11932209","id":"PMC_11932209","title":"Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1.","date":"2002","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11932209","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16638864","id":"PMC_16638864","title":"Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16638864","citation_count":119,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23322723","id":"PMC_23322723","title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23322723","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15102677","id":"PMC_15102677","title":"Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15102677","citation_count":102,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11422735","id":"PMC_11422735","title":"Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease.","date":"2001","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11422735","citation_count":101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11288810","id":"PMC_11288810","title":"Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects.","date":"2001","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/11288810","citation_count":97,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12193581","id":"PMC_12193581","title":"Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12193581","citation_count":96,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24837548","id":"PMC_24837548","title":"Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies.","date":"2014","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24837548","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12213905","id":"PMC_12213905","title":"Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12213905","citation_count":87,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11841224","id":"PMC_11841224","title":"Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11841224","citation_count":82,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12161536","id":"PMC_12161536","title":"Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12161536","citation_count":80,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12446468","id":"PMC_12446468","title":"Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers.","date":"2002","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12446468","citation_count":80,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11711521","id":"PMC_11711521","title":"Carotid and femoral artery stiffness in relation to three candidate genes in a white population.","date":"2001","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11711521","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55321,"output_tokens":6704,"usd":0.133262},"stage2":{"model":"claude-opus-4-6","input_tokens":10457,"output_tokens":3033,"usd":0.192165},"total_usd":0.708469,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":71291,"output_tokens":9038,"usd":0.174722},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13101,"output_tokens":2935,"usd":0.20832}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CYP11B2 encodes aldosterone synthase capable of catalyzing all three final steps of aldosterone biosynthesis (11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone), whereas CYP11B1 can only perform 11β-hydroxylation; expression of CYP11B2 cDNA in COS-1 cells demonstrated aldosterone synthesis from deoxycorticosterone.\",\n      \"method\": \"cDNA expression in COS-1 cells with steroid product analysis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic reconstitution in heterologous cells, foundational paper with 315 citations\",\n      \"pmids\": [\"1775135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CYP11B2 (P-450aldo) preferentially catalyzes conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone, whereas CYP11B1 (P-450(11)β) substantially fails to produce aldosterone; demonstrated by expression in COS-7 cells.\",\n      \"method\": \"cDNA cloning and expression in COS-7 cells with steroid product analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic reconstitution in heterologous cells, independently corroborated by PMID 1775135\",\n      \"pmids\": [\"2256920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Mutations R181W and V386A in CYP11B2 cause corticosterone methyloxidase II (CMO-II) deficiency: R181W reduces 18-hydroxylase activity and abolishes 18-oxidase activity while leaving 11β-hydroxylase activity intact; V386A causes a small reduction in 18-hydroxycorticosterone production. Each mutation was individually introduced into CYP11B2 cDNA and expressed in cultured cells.\",\n      \"method\": \"Site-directed mutagenesis and cDNA expression in cultured cells with steroid product assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutagenesis with in vitro enzymatic assay, replicated in PMID 1346492\",\n      \"pmids\": [\"1594605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Glucocorticoid-suppressible hyperaldosteronism (GSH) is caused by a hybrid CYP11B1/CYP11B2 gene generated by unequal meiotic crossing-over, placing CYP11B2 aldosterone-synthase coding sequences under CYP11B1 promoter control. Transfection of hybrid cDNAs showed that hybrids containing up to the first three CYP11B1 exons synthesize aldosterone at near-normal CYP11B2 levels, while those with five or more CYP11B1 exons lose aldosterone synthesis.\",\n      \"method\": \"Unequal crossover mapping plus cDNA transfection expression assay with steroid product analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic epistasis combined with functional reconstitution, foundational paper 207 citations\",\n      \"pmids\": [\"1518866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Point mutations R181W (exon 3) and V386A (exon 7) in CYP11B2 occur in patients with CMO-II deficiency and are homozygous in affected individuals; confirmed by PCR-restriction enzyme analysis showing autosomal recessive inheritance.\",\n      \"method\": \"PCR-RFLP genotyping of patients and family members\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient genetic analysis corroborating functional data from PMID 1594605\",\n      \"pmids\": [\"1346492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Angiotensin II and K⁺ regulate human CYP11B2 transcription through two common cis-elements: a CRE-like element at −71/−64 (TGACGTGA) and an SF-1/COUP-TF binding element at −129/−114. Both elements are required for full basal activity and maximal induction by cAMP and calcium signaling pathways. The −71/−64 element binds CREB proteins and the −129/−114 element binds SF-1 and COUP-TF, demonstrated by DNase I footprinting and EMSA.\",\n      \"method\": \"Deletion/mutation analysis of CYP11B2 5′-flanking region in transient transfection (H295R cells), DNase I footprinting, EMSA\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (reporter assay, footprinting, EMSA), strong replication across agonists\",\n      \"pmids\": [\"9139807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Gene conversion of exons 3 and 4 of CYP11B2 to CYP11B1 sequence (introducing D141E, K151N, I246T) is associated with but does not cause CMO-II deficiency, as all single, double, and triple mutants retain normal 18-oxidase activity in steroidogenic MA-10 and JEG-3 cells.\",\n      \"method\": \"Site-directed mutagenesis and expression in COS-1, MA-10, and JEG-3 cells with steroid product assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional assay across multiple cell lines\",\n      \"pmids\": [\"8550772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Combined E198D and V386A mutations in CYP11B2 individually have modest effects, but together with R173K result in decreased 11β-hydroxylase, large decrease in 18-hydroxylase, and no detectable 18-oxidase activity, demonstrated by transfection assays with individual and combined substitutions.\",\n      \"method\": \"Site-directed mutagenesis and transfection expression assay in cultured cells\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional enzymatic readout\",\n      \"pmids\": [\"9814506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mutation T318M in CYP11B2 (father's allele) combined with V386A abolishes measurable enzymatic activity, while the mother's allele carries R181W and a deletion/frameshift (δC372). Neither parental allele contributed detectable activity in cDNA expression assays, indicating that factors beyond CYP11B2 may influence the CMOI vs CMOII phenotypic distinction.\",\n      \"method\": \"DNA sequencing, site-directed mutagenesis, cDNA expression in cultured cells with steroid product assay\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional reconstitution, single lab but rigorous\",\n      \"pmids\": [\"7485152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Calcium signaling pathways regulate human CYP11B2 transcription; angiotensin II, K⁺, BAYK8644, ionomycin, and dibutyryl-cAMP all increase CYP11B2 reporter gene expression in H295R adrenocortical cells but not in Y-1 cells, demonstrating cell-context-dependent calcium regulation.\",\n      \"method\": \"Transient transfection luciferase reporter assay in Y-1 and H295R adrenocortical cells\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with pharmacological dissection, single lab\",\n      \"pmids\": [\"8969900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Amino acid substitutions I112P and D147E in CYP11B2, replacing residues with corresponding CYP11B1 residues, increase 11β-hydroxylation activity (up to sixfold when combined); I112P also enhances 18-hydroxylase activity by 70%, suggesting residue 112 is involved in the substrate access channel and residue 147 is on the protein surface influencing substrate conversion. Molecular dynamics/homology modeling supported these functional findings.\",\n      \"method\": \"Site-directed mutagenesis of CYP11B2 with in vitro enzymatic activity assay and homology modeling\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis combined with structural modeling\",\n      \"pmids\": [\"11856349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Rat CYP11B1 and CYP11B2 were expressed in E. coli; DR-CYP11B1 (from Dahl salt-resistant rats) has lower 18-hydroxylase and 19-hydroxylase activities than wild-type, with V381L+I384L accounting for reduced 18-OHase and V443M for reduced 19-OHase activity, demonstrating structure-function relationships for specific residues.\",\n      \"method\": \"E. coli expression of wild-type and mutant CYP11B proteins with enzymatic activity assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — heterologous reconstitution with systematic mutagenesis\",\n      \"pmids\": [\"9874258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A polymorphism in the CYP11B2 promoter at −344 (T/C) influences binding of the transcriptional regulatory protein SF-1, and another polymorphism is an intron 2 gene conversion; these polymorphisms are in linkage disequilibrium, defining haplotypes with potential functional consequences for aldosterone synthesis.\",\n      \"method\": \"Polymorphism analysis and transcription factor binding assessment\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — binding inference from sequence analysis; functional consequence partially supported by reporter assays in other papers\",\n      \"pmids\": [\"7588407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCB126 upregulates CYP11B2 mRNA expression through posttranscriptional mRNA stabilization (not AhR-mediated transcriptional activation), as demonstrated by promoter analyses showing little effect on transcription rate and RNA degradation assays showing PCB126 protects CYP11B2 transcripts from degradation; an internal region of CYP11B1 mRNA (nucleotides 881–1285) is important for this stabilization.\",\n      \"method\": \"Promoter reporter assay, RNA degradation assay, AhR antagonist treatment in H295R cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (reporter + RNA stability assay), single lab\",\n      \"pmids\": [\"16396990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Novel CYP11B2 missense mutations S315R and R374W completely abolish conversion of 11-deoxycorticosterone to aldosterone when expressed in COS-1 cells; 3-D homology modeling indicated that these mutations change the hydrogen bond network in the protein, explaining the loss of function.\",\n      \"method\": \"Expression of mutant proteins in COS-1 cells with steroid product assay and 3-D structural modeling\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution with structural modeling\",\n      \"pmids\": [\"20494601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CYP11B2 mutation S308P (located within α-helix I near the heme-binding active site) completely abolishes enzyme activity in vitro, yet some in vivo aldosterone production persists, suggesting possible residual activity or alternative pathway; structural modeling placed S308P proximal to the active site.\",\n      \"method\": \"In vitro functional characterization of S308P mutant protein, structural modeling, dexamethasone suppression in patients\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with structural modeling and in vivo corroboration\",\n      \"pmids\": [\"19116236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-10b, induced by hypoxia via HIF-1α, negatively regulates CYP11B2 and CYP11B1 mRNA by targeting their 3′-UTRs, as validated by luciferase reporter assays with 3′-UTR constructs combined with miRNA overexpression and knockdown in H295R cells.\",\n      \"method\": \"Luciferase 3′-UTR reporter assay, miRNA overexpression and knockdown in H295R cells\",\n      \"journal\": \"Marine pollution bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter plus overexpression/knockdown, single lab\",\n      \"pmids\": [\"24768260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-193a-3p directly targets the CYP11B2 3′-UTR, demonstrated by luciferase reporter assay with wild-type vs. mutant binding site; overexpression of miR-193a-3p in H295R cells downregulates CYP11B2 mRNA and protein, inhibits aldosterone secretion, reduces proliferation, induces G1-phase arrest and promotes apoptosis.\",\n      \"method\": \"Luciferase 3′-UTR reporter assay, qRT-PCR, Western blot, flow cytometry, ELISA in H295R cells\",\n      \"journal\": \"International journal of experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods confirming direct targeting, single lab\",\n      \"pmids\": [\"29665181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-138-5p targets CYP11B2 (validated by RNA immunoprecipitation assay and luciferase assay in AC16 cells); overexpression of miR-138-5p suppresses cell growth and CYP11B2 expression, while knockdown promotes cell growth, linking CYP11B2 to atrial fibrillation-associated cell proliferation.\",\n      \"method\": \"Luciferase reporter assay, RNA immunoprecipitation, Western blot, cell proliferation assay in AC16 cells\",\n      \"journal\": \"European review for medical and pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal RIP and luciferase validation, single lab\",\n      \"pmids\": [\"30058705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Torasemide inhibits human CYP11B2 (aldosterone synthase) activity in transfected V79MZ lung fibroblast cells by 75%, and the selective CYP11B2 inhibitor SL242 mimics this effect, reducing CTGF, LOX, and miR-21 expression in cardiac fibroblasts and preventing atrial fibrosis and atrial fibrillation in RacET mice.\",\n      \"method\": \"CYP11B2 activity assay in transfected cells, in vivo mouse model with histology and electrophysiology\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic inhibition assay plus in vivo phenotypic validation, single lab\",\n      \"pmids\": [\"26047574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Atractylenolide-I (AT-I) selectively and covalently binds to CYP11B2 at Cys450 (enabled by Ala320 creating selectivity over CYP11B1); the C8/C9 double bond of AT-I is epoxidized and undergoes nucleophilic addition with Cys450's sulfhydryl group, disrupting heme-CYP11B2 interaction and inactivating the enzyme, thereby suppressing aldosterone synthesis without affecting cortisol.\",\n      \"method\": \"Chemical biology binding studies, mass spectrometry, molecular docking, cell-based aldosterone/cortisol assays, in vivo hyperaldosteronism model\",\n      \"journal\": \"Acta pharmaceutica sinica. B\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — covalent binding mechanism defined by chemical biology and structural analysis with functional validation\",\n      \"pmids\": [\"35127376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A deletion hybrid gene consisting of the CYP11B2 promoter and exons 1–6 fused to CYP11B1 exons 7–9 (with an I339T intracodon mutation at the breakpoint) retains relatively unimpaired 11β-hydroxylase and aldosterone synthase activities when expressed in COS-1 cells; 11β-hydroxylase deficiency in the patient arises from lack of fasciculata expression due to replacement of the CYP11B1 promoter by the CYP11B2 promoter.\",\n      \"method\": \"Mutant cDNA expression in COS-1 cells with steroid product assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution of hybrid gene, clear mechanistic conclusion\",\n      \"pmids\": [\"11443188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"In the rat adrenal cortex, P450aldo (CYP11B2) and P45011β (CYP11B1) are localized to distinct zones (zona glomerulosa and zona fasciculata, respectively) with a CYP11B2/CYP11B1-negative 'white zone' of stem cells between them; angiotensin II stimulation induced by Na-deficiency increases CYP11B2-positive zona glomerulosa cell number and promotes their proliferation, establishing CYP11B2 expression as a functional marker of aldosterone-producing zona glomerulosa cells.\",\n      \"method\": \"Dual immunostaining with anti-P450aldo and anti-P45011β antibodies, BrdU pulse-chase in rat adrenal\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization tied to functional consequence (zone-specific steroidogenesis and proliferation), replicated across labs\",\n      \"pmids\": [\"7588405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HDL2 stimulates aldosterone synthesis in H295R adrenocortical cells by increasing CYP11B2 expression up to 19-fold; the effect is mediated by a calcium signaling cascade, as a calcium channel blocker and calmodulin kinase inhibitor abolished the CYP11B2-stimulating effects.\",\n      \"method\": \"H295R cell treatment with HDL fractions, RT-PCR for CYP11B2 mRNA, pharmacological inhibition of calcium signaling, ELISA for aldosterone\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with pharmacological tools and dose-response, single lab\",\n      \"pmids\": [\"21239432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DNA methylation negatively controls CYP11B2 expression; methylation of recognition sites for CREB1 and NGFIB diminishes their DNA-binding activity; methyl-CpG-binding protein 2 (MeCP2) cooperates directly with methylated CpG dinucleotides of CYP11B2; hypomethylation of the CYP11B2 promoter region is found in aldosterone-producing adenomas; low-salt diet, angiotensin II, and potassium increase CYP11B2 mRNA and induce DNA hypomethylation.\",\n      \"method\": \"DNA methylation analysis, transcription factor binding studies, in vitro and in vivo aldosterone stimulation experiments\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods across human and cell-model contexts, review synthesizing experimental data\",\n      \"pmids\": [\"36982850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP11B2 promoter region is hypomethylated in aldosterone-producing adenomas (APA) compared to nonfunctioning adenomas; KCNJ5 mutation introduction via lentivirus in HAC15 cells did not change CYP11B2 methylation levels, indicating hypomethylation is not directly caused by KCNJ5 or ATP1A1 mutations.\",\n      \"method\": \"DNA methylation array, qPCR, lentiviral KCNJ5 mutation introduction in HAC15 cells\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — methylation array plus functional cell experiment, single lab\",\n      \"pmids\": [\"27754862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Monoclonal antibodies specific for CYP11B2 (targeting amino acids 41–52) and CYP11B1 (targeting amino acids 80–90) were generated; triple immunofluorescence confirmed CYP11B2 and CYP11B1 do not co-localize in the adrenal, while CYP11B1 co-localizes with 17α-hydroxylase, establishing zone-specific subcellular/tissue localization of these enzymes.\",\n      \"method\": \"Monoclonal antibody generation, Western blot, triple immunofluorescence of adrenal sections\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with specific antibodies validated by multiple methods, widely replicated tool paper (245 citations)\",\n      \"pmids\": [\"24325867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Functional analysis of heterozygous human adrenal tissue showed decreased CYP11B2 expression associated with the intron 2 conversion polymorphism allele that reduces hypertension risk, while increased CYP11B1 expression was associated with the same alleles, suggesting a digenic mechanism of altered relative CYP11B1/CYP11B2 expression affecting corticosteroid synthesis.\",\n      \"method\": \"Allele-specific expression analysis in human adrenal tissue, large case-control genetic study\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct tissue expression measurement linked to genetic variant, single lab with large cohort\",\n      \"pmids\": [\"23150505\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11B2 encodes aldosterone synthase, a mitochondrial cytochrome P450 expressed in the adrenal zona glomerulosa that catalyzes the sequential 11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone to aldosterone; its transcription is regulated by angiotensin II and K⁺ via shared CRE/SF-1 cis-elements and calcium/cAMP signaling pathways, by DNA methylation status at its promoter, and by microRNAs (miR-10b, miR-193a-3p, miR-138-5p) targeting its 3′-UTR; loss-of-function mutations at key residues (R181W, V386A, T318M, S308P, S315R, R374W) differentially abolish its three sequential catalytic activities, and a hybrid CYP11B1/CYP11B2 gene underlies glucocorticoid-suppressible hyperaldosteronism.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CYP11B2 was identified as a second human steroid 11β-hydroxylase gene (alongside CYP11B1), each containing nine exons. The CYP11B2-encoded protein shares 93% amino acid identity with CYP11B1, but the 5'-flanking regions of the two genes diverge considerably, and CYP11B2 transcripts were not detected in normal adrenal mRNA at the time of initial characterization.\",\n      \"method\": \"Genomic cloning, sequencing, exon-intron mapping, and comparative analysis of CYP11B1 and CYP11B2 genes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational cloning and sequencing study, highly cited, establishes gene structure\",\n      \"pmids\": [\"2592361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The CYP11B2-encoded protein (P-450aldo) was shown by cDNA expression in COS-7 cells to preferentially catalyze the full conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone, whereas the closely related P-450(11)β (CYP11B1 product) substantially fails to catalyze aldosterone formation, establishing CYP11B2 as the aldosterone synthase.\",\n      \"method\": \"cDNA cloning from adrenal tumor, expression in COS-7 cells, steroid product analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution in heterologous cells, directly demonstrates enzymatic distinction between paralogs\",\n      \"pmids\": [\"2256920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Expression of CYP11B2 cDNA in COS-1 cells demonstrated that its protein product can 11β-hydroxylate, 18-hydroxylate, and 18-oxidize corticosteroids, synthesizing aldosterone from deoxycorticosterone, whereas CYP11B1 product only 11β-hydroxylates. CYP11B2 mRNA is induced in adrenal zona glomerulosa cells by angiotensin II, confirming CYP11B2 is required for aldosterone biosynthesis.\",\n      \"method\": \"PCR-based expression analysis, cDNA cloning, transient transfection of COS-1 cells, steroid product measurement\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution in heterologous cells with product analysis, replicated across normal and tumor tissue\",\n      \"pmids\": [\"1775135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CYP11B2 encodes both steroid 11β-hydroxylase and 18-hydroxylase (P-450C18/aldosterone synthase) activities. Expression in COS-7 cells confirmed that CYP11B2 product catalyzes synthesis of aldosterone and 18-oxocortisol, whereas CYP11B1 product exclusively exhibits 11β-hydroxylase activity. Promoter deletion analysis showed the two genes are regulated by distinct transcriptional mechanisms.\",\n      \"method\": \"Genomic cloning, cDNA expression in COS-7 cells, CAT reporter gene assays with deletion mutants of promoter regions in Y-1 adrenal tumor cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic reconstitution plus promoter functional analysis, independently consistent with other expression studies\",\n      \"pmids\": [\"1741400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Glucocorticoid-suppressible hyperaldosteronism (GSH) is caused by unequal meiotic crossing-over between CYP11B1 and CYP11B2, generating a hybrid gene with CYP11B1 5'-regulatory/coding sequences and CYP11B2 3'-coding sequences. Cells transfected with hybrid cDNAs containing up to three CYP11B1 exons synthesized aldosterone at near-normal levels, but hybrids with five or more CYP11B1 exons could not produce detectable aldosterone, mapping the aldosterone synthase functional determinants to the 3' coding region of CYP11B2.\",\n      \"method\": \"Southern blot, PCR detection of hybrid genes in patients, transient transfection of hybrid cDNAs in cultured cells with steroid product measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution with mutagenesis (exon swapping), mechanistically maps aldosterone synthase activity to CYP11B2 coding sequences\",\n      \"pmids\": [\"1518866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Glucocorticoid-remediable aldosteronism in 12 kindreds is caused by chimeric gene duplications fusing CYP11B1 regulatory sequences to CYP11B2 coding sequences via unequal crossing-over at introns 2–4, placing aldosterone synthase under ACTH/glucocorticoid-suppressible regulation. Sites of crossing-over range from intron 2 to intron 4.\",\n      \"method\": \"Southern blot and PCR analysis of chimeric gene structure in affected kindreds\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mechanism established in 12 independent kindreds, consistent with biochemical phenotype\",\n      \"pmids\": [\"1303253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Two point mutations in CYP11B2 — R181W (exon 3) and V386A (exon 7) — were identified as the molecular basis of corticosterone methyloxidase II (CMO-II) deficiency. When expressed in cultured cells, R181W abolished 18-oxidase activity and reduced 18-hydroxylase activity while preserving 11β-hydroxylase activity; V386A caused a smaller reduction in 18-hydroxycorticosterone production. These mutations map the 18-oxidase and 18-hydroxylase functions to specific CYP11B2 residues.\",\n      \"method\": \"Mutation identification by sequencing, site-directed mutagenesis of CYP11B2 cDNA, expression in cultured cells with steroid product assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional reconstitution in cells, activity mapped to specific residues\",\n      \"pmids\": [\"1594605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Point mutations R181W and V386A in CYP11B2 (P-450C18) were confirmed in CMO-II deficiency patients by PCR-restriction analysis, with patients homozygous for both mutations and unaffected parents heterozygous, consistent with autosomal recessive inheritance.\",\n      \"method\": \"PCR-restriction enzyme analysis of CYP11B2 mutations in patients and family members\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independent confirmation of disease-causing mutations in CYP11B2\",\n      \"pmids\": [\"1346492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Rat cytochrome P-450aldo (CYP11B2 ortholog) and P-450(11)β genes share similar intron-exon organization but have divergent 5'-flanking regions. A putative cAMP-responsive element (TGACGTGA) is present in the P-450aldo gene but altered in P-450(11)β, suggesting differential transcriptional regulation. S1 nuclease assay identified a single transcription initiation site for P-450aldo.\",\n      \"method\": \"Genomic cloning, sequencing, S1 nuclease protection assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 structural data (sequencing, S1 mapping) but in rat ortholog, single lab\",\n      \"pmids\": [\"1953771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A mutation T318M in CYP11B2 was identified in a patient with CMO-II deficiency. When this mutation (along with parental allele mutations R181W, delta C372, and V386A) was expressed in cDNA vectors, neither allele contributed measurable aldosterone synthase activity, yet the clinical phenotype was CMO-II (not CMO-I), suggesting that factors beyond CYP11B2 enzymatic activity modulate the severity of the deficiency phenotype.\",\n      \"method\": \"Direct DNA sequencing, cDNA expression in cultured cells with steroid assay\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis and expression, but interpretation complicated by genotype-phenotype discordance\",\n      \"pmids\": [\"7485152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A gene conversion in exons 3-4 of CYP11B2 (introducing D141E, K151N, I246T changes) was identified in CMO-II deficiency patients, but functional expression in COS-1, MA-10, and JEG-3 cells showed that these triple mutations retain normal 18-oxidase activity, demonstrating the gene conversion per se does not cause CMO-II deficiency and pointing to unidentified mutations elsewhere.\",\n      \"method\": \"Sequencing of CYP11B2, site-directed mutagenesis, expression in COS-1, MA-10, and JEG-3 cells, steroid product assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — thorough mutagenesis (7 constructs) with functional assay in multiple cell lines\",\n      \"pmids\": [\"8550772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Calcium signaling via L-type calcium channel activation and ionomycin treatment increases human CYP11B2 reporter gene expression in H295R adrenocortical cells but not in Y-1 cells, demonstrating that calcium-signaling pathways regulate CYP11B2 transcription, and that H295R is the appropriate model for this study.\",\n      \"method\": \"Transient transfection of luciferase reporter constructs containing CYP11B2 5'-flanking DNA in H295R and Y-1 adrenocortical cell lines\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with pharmacological interventions in relevant cell line, single lab\",\n      \"pmids\": [\"8969900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Angiotensin II, K+, and cAMP signaling pathways regulate human CYP11B2 transcription through two distinct cis-elements: a CRE-like element at -71/-64 (TGACGTGA) that binds CREB proteins, and an SF-1/COUP-TF binding element at -129/-114. Both elements are required for full basal activity and maximal induction, as shown by deletion, mutation, DNase I footprinting, and EMSA analyses.\",\n      \"method\": \"Transient transfection of deletion/mutation reporter constructs in H295R cells, DNase I footprinting, EMSA with nuclear extracts\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (footprinting, EMSA, deletion/mutation reporters), identifies specific cis-elements and binding proteins\",\n      \"pmids\": [\"9139807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Angiotensin II and KCl stimulate CYP11B2 promoter activity in NCI-H295 cells via common cis-elements. A cis-element at -143/-161 is required for high-level promoter activity upon stimulation. Calcium channel blockade abolishes KCl stimulation, while protein kinase C inhibition (bisindolylmaleimide) enhances promoter activity, indicating PKC negatively regulates CYP11B2 transcription, and the PKA pathway positively regulates it.\",\n      \"method\": \"Transient transfection of hamster CYP11B2 deletion/mutation reporter constructs in NCI-H295 cells, pharmacological inhibitors of calcium channels and PKC\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assays with pharmacological dissection, hamster ortholog in human cell line\",\n      \"pmids\": [\"9584833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Two mutations E198D and V386A in CYP11B2 together cause aldosterone synthase deficiency type I in two twins. When expressed individually, these and R173K have modest effects; together, they cause decreased 11β-hydroxylase activity, large decrease of 18-hydroxylase, and absent 18-oxidase activity, demonstrating that combined mutations can produce a more severe phenotype than either alone.\",\n      \"method\": \"Sequencing of CYP11B2, transfection assays of mutant cDNA combinations in cultured cells with steroid product measurement\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with functional reconstitution, individually and in combination\",\n      \"pmids\": [\"9814506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Rat CYP11B2 and the mutant DR-CYP11B1 (from Dahl salt-resistant rats) were expressed in Escherichia coli. The V381L and I384L double mutation in CYP11B1 accounts for its low 18-hydroxylase activity. V443M is responsible for decreased 19-hydroxylase activity. These results functionally assign 18-hydroxylase and 19-hydroxylase activities to specific residues in the CYP11B sequence.\",\n      \"method\": \"Site-directed mutagenesis, expression of rat CYP11B1 and CYP11B2 in E. coli, in vitro steroid hydroxylation assays\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with site-directed mutagenesis maps specific activities to residues\",\n      \"pmids\": [\"9874258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The CRE/Ad1 cis-element is required for basal expression and agonist-stimulated transcription of both CYP11B1 and CYP11B2, but mutation of the CRE in CYP11B2 abolishes basal expression yet retains agonist (angiotensin II, cAMP) response, suggesting additional cis-elements mediate hormonal regulation of CYP11B2. EMSA demonstrated binding of CREB, ATF-1, and ATF-2 to the CRE elements, with ATF-2 forming the complex most similar to that seen in H295R nuclear extracts.\",\n      \"method\": \"Transient transfection of CYP11B1 and CYP11B2 reporter constructs with CRE mutations in H295R cells, EMSA with in vitro transcription factor proteins and nuclear extracts\",\n      \"journal\": \"Endocrine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of cis-element combined with EMSA identifies transcription factor binding\",\n      \"pmids\": [\"11196473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Steroidogenic factor-1 (SF-1) paradoxically inhibits CYP11B2 reporter activity while stimulating CYP11B1, CYP11A1, and CYP17 reporters, making CYP11B2 the first steroid hydroxylase not positively regulated by SF-1. The -344C/T polymorphism in the Ad4 (SF-1 binding) element of CYP11B2 influences SF-1 binding in EMSA (C allele binds more strongly), but does not alter agonist-stimulated reporter expression in H295R cells.\",\n      \"method\": \"Transient co-transfection of reporter constructs with SF-1 expression vectors in H295R and Y-1 cells, EMSA with SF-1 and -344C/T allele probes\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution with multiple reporters and EMSA, distinguishes SF-1 regulation of paralogs\",\n      \"pmids\": [\"11932209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Calmodulin-dependent kinase I (CaMKI) is the primary calcium-dependent kinase regulating CYP11B2 transcription. Constitutively active CaMKI stimulated CYP11B2 reporter expression in H295R cells via the cAMP regulatory element at -71/-64, while CaMKII had no effect and CaMKIV had a small effect. CaMKI expression was confirmed in adrenal cortex and H295R cells by immunohistochemistry and Western/Northern blot.\",\n      \"method\": \"Transient transfection of CaMK expression vectors and CYP11B2 reporter constructs in H295R cells, pharmacological inhibitors (KN93, calmidazolium), mutational analysis of promoter, immunohistochemistry, Western and Northern blot\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods identifying CaMKI as the specific kinase, with promoter mutagenesis linking it to a defined cis-element\",\n      \"pmids\": [\"12193581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The amino acid substitutions I112P and D147E in human CYP11B2 increase 11β-hydroxylation activity (up to 6-fold when combined), while I112P enhances 18-hydroxylase activity by 70%. The 18-oxidase activity is slightly reduced by most mutations except D147E. Residue I112 in the putative substrate access channel and D147 on the protein surface influence substrate recognition and conversion in CYP11B2.\",\n      \"method\": \"Site-directed mutagenesis of CYP11B2 residues, expression of mutant proteins in E. coli, in vitro steroid hydroxylation assays, computer homology modeling\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis with enzymatic assay maps specific residues to reaction steps\",\n      \"pmids\": [\"11856349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human CYP11B2 was functionally expressed in fission yeast (Schizosaccharomyces pombe), where its mitochondrial targeting signal is functional (confirmed by Western blot, fluorescence, and electron microscopy). A novel fission yeast ferredoxin-domain protein, etp1, can replace adrenodoxin in electron transfer to CYP11B2, enabling steroid hydroxylation in a reconstituted assay. CYP11B2 in intact yeast cells converts 11-deoxycorticosterone to corticosterone, 18-hydroxycorticosterone, and aldosterone.\",\n      \"method\": \"Heterologous expression in S. pombe, Western blot, fluorescence and electron microscopy for localization, in vivo and reconstituted in vitro steroid hydroxylation assays with recombinant etp1\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with multiple orthogonal localization methods, identifies novel electron transfer partner etp1\",\n      \"pmids\": [\"11841224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCB126 upregulates CYP11B2 mRNA in H295R human adrenocortical cells not through aryl hydrocarbon receptor (AhR)-mediated transcriptional activation, but by increasing posttranscriptional mRNA stability, as demonstrated by AhR antagonist experiments (which failed to block induction) and RNA degradation assays. An internal region of CYP11B1 mRNA (nucleotides 881-1285) was identified as important for PCB126-mediated transcript stabilization.\",\n      \"method\": \"AhR antagonist (3',4'-DMF) treatment, RNA degradation assays, promoter analyses, RT-PCR in H295R cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection and RNA stability assay in relevant cell line, single lab\",\n      \"pmids\": [\"16396990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A deletion hybrid CYP11B gene (CYP11B2 promoter + exons 1-6 fused to CYP11B1 exons 7-9 plus an I339T intracodon mutation) was characterized in a patient with 11β-hydroxylase deficiency/congenital adrenal hyperplasia. Expression of the corresponding cDNA in COS-1 cells showed relatively unimpaired 11β-hydroxylase and aldosterone synthase activities, demonstrating that the 11β-hydroxylase deficiency results from absence of CYP11B1 zona fasciculata expression rather than enzymatic incapacity.\",\n      \"method\": \"Gene structure determination, cDNA expression in COS-1 cells, steroid product assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in COS-1 cells, but single patient/case\",\n      \"pmids\": [\"11443188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CYP11B2 promoter activity is regulated by Alu retrotransposable elements (functioning as enhancers) and conserved proximal cis-elements including Ad5 (bound by ERRα during basal expression) and SF-1 sites. Mutation of the Ad5 site reduces promoter activity to minimal levels. CYP11B1-specific L1 element (CYP11B1-L1.2) inserted between Alu and the conserved region blocks Alu enhancement in CYP11B1 but not CYP11B2, explaining part of the differential regulation of the two paralogs.\",\n      \"method\": \"Reporter gene assays with deletion/mutation constructs, EMSA, sequence analysis, transposable element functional dissection in adrenocortical cell lines\",\n      \"journal\": \"Steroids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter dissection with EMSA, identifies ERRα as Ad5 binding transcription factor\",\n      \"pmids\": [\"22079243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structures of human aldosterone synthase (CYP11B2) in complex with substrate deoxycorticosterone and inhibitor fadrozole were solved. The structures reveal a hydrophobic active site with features for corticosteroid recognition. Divergent residues conferring 18-oxidase activity (unique to CYP11B2 vs. CYP11B1) are located in the I-helix (near O2 activation) and loops around the H-helix (affecting an egress channel required for retaining intermediates). Fadrozole binds in R-configuration using part of the active site cavity. Low processivity (high release of intermediates) is identified as a mechanism of controlled aldosterone production.\",\n      \"method\": \"X-ray crystallography of CYP11B2 with substrate and inhibitor, biochemical substrate conversion assays\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with biochemical validation, provides atomic-level mechanism for substrate specificity and catalysis\",\n      \"pmids\": [\"23322723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Five novel CYP11B2 mutations causing aldosterone synthase deficiency type I (W260X, G206WfsX51, L496SfsX169, S315R, R374W) were identified. Expression of S315R and R374W in COS-1 cells showed complete absence of CYP11B2 activity for conversion of 11-deoxycorticosterone to aldosterone. 3D modeling indicated these mutations disrupt hydrogen bond networks in the enzyme.\",\n      \"method\": \"Sequencing, expression of mutant CYP11B2 in COS-1 cells, steroid product assay, 3D structural modeling\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional expression with activity assay for multiple mutants, structural modeling support\",\n      \"pmids\": [\"20494601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A novel CYP11B2 mutation S308P (T925C in exon 5) was identified in siblings with hyperreninemic hypoaldosteronism. Functional characterization in vitro showed complete loss of enzyme activity. Structural modeling placed S308 within the alpha-helix I near the heme-binding active site. However, in vivo dexamethasone treatment further reduced aldosterone levels, suggesting some residual mineralocorticoid biosynthesis occurs through alternative pathways or residual mutant activity.\",\n      \"method\": \"Sequencing, in vitro functional expression of S308P mutant, structural modeling, dexamethasone suppression test in vivo\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with structural modeling localizes mutation to active site; in vivo test provides additional context\",\n      \"pmids\": [\"19116236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HDL2 stimulates aldosterone synthesis in H295R human adrenocortical cells by increasing CYP11B2 mRNA expression up to 19-fold. This effect is mediated through a calcium signaling cascade (abolished by calcium channel blockers and calmodulin kinase inhibitors) and is not additive with angiotensin II or K+ stimulation.\",\n      \"method\": \"H295R cell treatment with HDL subfractions, CYP11B2 mRNA quantification, aldosterone measurement, pharmacological inhibitors of calcium signaling\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with dose-response and time-course data, single lab\",\n      \"pmids\": [\"21239432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-10b, induced by hypoxia and HIF-1α in H295R adrenocortical cells, negatively regulates CYP11B2 (and CYP11B1) mRNA through their 3'-UTRs. Luciferase assays with 3'-UTR constructs, combined with miRNA overexpression and knockdown, established CYP11B2 as a direct post-transcriptional target of miR-10b.\",\n      \"method\": \"miRNA arrays, luciferase reporter assays with CYP11B2 3'-UTR in H295R cells, miRNA overexpression and knockdown, HIF-1α overexpression\",\n      \"journal\": \"Marine pollution bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter and miRNA gain/loss-of-function establish direct post-transcriptional regulation\",\n      \"pmids\": [\"24768260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Torasemide (but not furosemide) inhibits human CYP11B2 enzymatic activity by 75% in transfected lung fibroblasts (V79MZ cells), independently of mineralocorticoid receptor. In mice with cardiac Rac1 overexpression, torasemide prevented atrial fibrosis and atrial fibrillation correlated with suppression of CTGF, LOX, and miR-21; the selective CYP11B2 inhibitor SL242 mimicked torasemide effects, establishing CYP11B2 activity as a contributor to atrial fibrosis.\",\n      \"method\": \"CYP11B2 activity assay in transfected cells, cardiac fibroblast assays, in vivo mouse model with torasemide/furosemide treatment, gene expression and histology\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzyme assay plus in vivo model with specific inhibitor control, single lab\",\n      \"pmids\": [\"26047574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-193a-3p directly targets the 3'-UTR of CYP11B2 in H295R adrenocortical cells, as validated by luciferase reporter assay and site-directed mutation of the binding site. Overexpression of miR-193a-3p reduces CYP11B2 mRNA and protein, decreases aldosterone secretion, inhibits proliferation, and promotes apoptosis. Restoration of CYP11B2 rescues these effects, establishing CYP11B2 as a functional target of miR-193a-3p in aldosterone-producing adenoma.\",\n      \"method\": \"Luciferase reporter assays with wild-type and mutant CYP11B2 3'-UTR, miRNA mimic transfection in H295R cells, qRT-PCR, Western blot, aldosterone ELISA, flow cytometry\",\n      \"journal\": \"International journal of experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter with mutation confirms direct target, functional rescue experiment adds specificity\",\n      \"pmids\": [\"29665181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Atractylenolide-I (AT-I) selectively inhibits CYP11B2 through a covalent mechanism: the C8/C9 double bond of AT-I is epoxidized and then undergoes nucleophilic addition with Cys450 of CYP11B2 (enabled by the presence of Ala320 in CYP11B2, absent in CYP11B1). This covalent binding disrupts the interaction between heme and CYP11B2, inactivating the enzyme and suppressing aldosterone synthesis without affecting CYP11B1-mediated cortisol production.\",\n      \"method\": \"Chemical biology/activity-based protein profiling, molecular docking, mutagenesis, cell-based aldosterone/cortisol measurement, in vivo hyperaldosteronism model\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — covalent binding mechanism characterized by chemical biology and structural modeling with functional validation, single lab\",\n      \"pmids\": [\"35127376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DNA methylation negatively controls CYP11B2 expression; hypomethylation of the CYP11B2 promoter is seen in aldosterone-producing adenomas. Methylation of recognition sites for CREB1 and NGFIB (nerve growth factor-induced clone B) reduces their DNA-binding activity. Methyl-CpG-binding protein 2 (MeCP2) directly cooperates with methylated CpG dinucleotides of the CYP11B2 promoter. Low-salt diet, angiotensin II, and K+ stimulation increase CYP11B2 mRNA and induce promoter DNA hypomethylation.\",\n      \"method\": \"DNA methylation array, bisulfite sequencing, reporter assays, EMSA, adrenal tissue analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epigenetic regulation supported by multiple methods and tissue data\",\n      \"pmids\": [\"36982850\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 enzyme that catalyzes the final three steps of aldosterone biosynthesis—11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone—with distinct active-site features (I-helix near O2 activation, H-helix egress channel loops, and Cys450) that confer its unique 18-oxidase activity compared to the paralogous CYP11B1; its transcription in adrenal zona glomerulosa is activated by angiotensin II and K+ via calcium/CaMKI signaling and cAMP pathways converging on a CRE-like element and an SF-1/COUP-TF site in its promoter, is paradoxically inhibited (not activated) by SF-1, and is negatively regulated post-transcriptionally by miR-10b, miR-193a-3p, and epigenetically by promoter DNA methylation through MeCP2 and CREB/NGFIB binding site methylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CYP11B2 encodes aldosterone synthase, a mitochondrial cytochrome P450 enzyme exclusively expressed in the adrenal zona glomerulosa that catalyzes the three sequential terminal reactions of aldosterone biosynthesis — 11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone — distinguishing it from the paralogous CYP11B1, which performs only 11β-hydroxylation [PMID:1775135, PMID:2256920]. Transcription of CYP11B2 is induced by angiotensin II and potassium through convergent calcium/cAMP signaling pathways acting on a CRE-like element (−71/−64) and an SF-1/COUP-TF element (−129/−114) in its promoter, and is further modulated by promoter DNA methylation status, with hypomethylation enhancing expression in aldosterone-producing adenomas [PMID:9139807, PMID:36982850]. Loss-of-function mutations at residues including R181W, V386A, T318M, S308P, S315R, and R374W differentially impair the three catalytic steps and underlie corticosterone methyloxidase deficiency, while a chimeric CYP11B1/CYP11B2 gene produced by unequal crossing-over causes glucocorticoid-suppressible hyperaldosteronism by placing aldosterone synthase coding sequences under ectopic ACTH-responsive promoter control [PMID:1594605, PMID:1518866, PMID:20494601]. The covalent inhibitor atractylenolide-I selectively inactivates CYP11B2 by binding Cys450 — a selectivity conferred by Ala320, which is replaced by a bulkier residue in CYP11B1 — disrupting heme coordination and suppressing aldosterone without affecting cortisol [PMID:35127376].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Resolution of which P450 isoform synthesizes aldosterone: CYP11B2 but not CYP11B1 catalyzes the complete conversion of deoxycorticosterone to aldosterone, establishing CYP11B2 as aldosterone synthase.\",\n      \"evidence\": \"cDNA expression in COS-7 cells with steroid product analysis\",\n      \"pmids\": [\"2256920\", \"1775135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure of the active site not determined\", \"Electron donor (adrenodoxin/adrenodoxin reductase) requirements not characterized in this system\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Genetic basis of two inherited disorders was traced to CYP11B2: loss-of-function mutations R181W and V386A cause CMO-II deficiency by differentially abolishing 18-hydroxylase and 18-oxidase activities, while a hybrid CYP11B1/CYP11B2 gene from unequal crossing-over causes glucocorticoid-suppressible hyperaldosteronism by placing aldosterone synthase under ACTH-responsive promoter control.\",\n      \"evidence\": \"Site-directed mutagenesis with cell expression assays (PMID:1594605), patient genotyping (PMID:1346492), and hybrid gene expression in COS cells (PMID:1518866)\",\n      \"pmids\": [\"1594605\", \"1346492\", \"1518866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for why R181W selectively ablates 18-oxidase while preserving 11β-hydroxylase not resolved at atomic level\", \"Penetrance modifiers for GSH phenotype not identified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Zone-specific expression of CYP11B2 in the adrenal cortex was established: CYP11B2 is restricted to the zona glomerulosa while CYP11B1 is in the zona fasciculata, with a stem-cell 'white zone' between them; angiotensin II expands the CYP11B2-positive cell population.\",\n      \"evidence\": \"Dual immunostaining with specific antibodies and BrdU pulse-chase in rat adrenal\",\n      \"pmids\": [\"7588405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling zone boundary specification between CYP11B2 and CYP11B1 domains not defined\", \"Human adrenal zonal architecture not confirmed at this point with equivalent tools\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The cis-regulatory logic for CYP11B2 transcriptional induction was defined: angiotensin II and K⁺ converge on a CRE element (−71/−64) bound by CREB proteins and an SF-1/COUP-TF element (−129/−114), both required for calcium- and cAMP-mediated induction.\",\n      \"evidence\": \"Promoter deletion/mutation reporter assays in H295R cells, DNase I footprinting, and EMSA\",\n      \"pmids\": [\"9139807\", \"8969900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation (histone modifications) at the endogenous locus not addressed\", \"Relative contribution of CREB versus other bZIP factors in vivo unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Combinatorial mutagenesis revealed epistatic interactions among CYP11B2 residues: individual E198D and V386A mutations have modest effects, but triple mutants (with R173K) lose all 18-oxidase activity, establishing cooperativity among substrate-contact residues.\",\n      \"evidence\": \"Site-directed mutagenesis and transfection expression assay in cultured cells\",\n      \"pmids\": [\"9814506\", \"9874258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal or cryo-EM structure of CYP11B2 not available to validate modeled residue interactions\", \"Kinetic parameters (Km, kcat) for individual catalytic steps not systematically measured\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Specific determinants of substrate access and catalytic efficiency were mapped: I112P (in the predicted substrate access channel) enhances both 11β- and 18-hydroxylase activities, providing a structural rationale for CYP11B2 vs CYP11B1 functional divergence.\",\n      \"evidence\": \"Site-directed mutagenesis with enzymatic activity assay and homology modeling\",\n      \"pmids\": [\"11856349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental structure to validate the modeled substrate access channel\", \"Whether these residues influence reaction regioselectivity or only catalytic rate is unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Additional disease-causing mutations S315R and R374W were shown to completely abolish aldosterone synthesis, with structural modeling attributing loss of function to disruption of the hydrogen-bond network near the active site.\",\n      \"evidence\": \"Expression of mutant proteins in COS-1 cells with steroid product assay and 3-D homology modeling\",\n      \"pmids\": [\"20494601\", \"19116236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure to confirm predicted hydrogen-bond disruptions\", \"Protein stability versus catalytic defect not distinguished for all mutants\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Post-transcriptional regulation of CYP11B2 was uncovered: miR-10b, miR-193a-3p, and miR-138-5p each directly target the CYP11B2 3′-UTR and suppress aldosterone synthase expression, adding a microRNA regulatory layer to CYP11B2 control.\",\n      \"evidence\": \"Luciferase 3′-UTR reporter assays with wild-type and mutant binding sites, miRNA overexpression/knockdown in H295R and AC16 cells\",\n      \"pmids\": [\"24768260\", \"29665181\", \"30058705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo physiological relevance of each miRNA in adrenal aldosterone regulation not demonstrated\", \"Relative potency and combinatorial effects of the three miRNAs not assessed\", \"Each miRNA-CYP11B2 interaction reported by a single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Epigenetic regulation of CYP11B2 was linked to disease: CYP11B2 promoter hypomethylation characterizes aldosterone-producing adenomas and is not a secondary consequence of common somatic mutations (KCNJ5, ATP1A1), while physiological stimuli (angiotensin II, potassium, low salt) also induce hypomethylation.\",\n      \"evidence\": \"DNA methylation arrays on adenoma tissue, lentiviral KCNJ5 mutation in HAC15 cells, stimulation experiments\",\n      \"pmids\": [\"27754862\", \"36982850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal directionality between hypomethylation and CYP11B2 overexpression not definitively established\", \"Identity of the demethylase(s) responsible not determined\", \"Each study from a single laboratory\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The molecular basis for selective pharmacological inhibition of CYP11B2 was elucidated: atractylenolide-I undergoes CYP11B2-catalyzed epoxidation and then covalently modifies Cys450, exploiting Ala320-mediated selectivity over CYP11B1, which bears a bulkier residue at the equivalent position.\",\n      \"evidence\": \"Chemical biology binding studies, mass spectrometry, molecular docking, cell-based steroid assays, in vivo hyperaldosteronism model\",\n      \"pmids\": [\"35127376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term selectivity and off-target profile of AT-I in vivo not fully characterized\", \"Whether Cys450 modification is reversible under physiological conditions not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution experimental structure of CYP11B2 (X-ray or cryo-EM) with bound substrate or inhibitor is needed to validate all homology-model-based residue assignments, clarify the structural basis for the three-step catalytic cycle, and enable rational drug design beyond covalent inhibitors.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental 3-D structure of human CYP11B2 reported in the timeline\", \"Mechanism of sequential three-step catalysis (11β-OH → 18-OH → 18-oxidation) at one active site not structurally resolved\", \"Adrenodoxin interaction interface and electron transfer pathway not characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 10, 14, 15, 20]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 22, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 9, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CREB1\",\n      \"NR5A1\",\n      \"NR2F1\",\n      \"MECP2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 that catalyzes the final three steps of aldosterone biosynthesis—11β-hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone—activities that distinguish it from its 93%-identical paralog CYP11B1, which lacks 18-oxidase capacity [PMID:2256920, PMID:23322723]. Crystal structures reveal that the unique 18-oxidase activity depends on divergent residues in the I-helix near the oxygen activation site and loops around the H-helix that form an egress channel retaining intermediates, with low processivity controlling aldosterone output [PMID:23322723]. Transcription in the adrenal zona glomerulosa is driven by angiotensin II and K⁺ via calcium/CaMKI signaling converging on a CRE-like element (−71/−64) and an SF-1/COUP-TF site, with SF-1 paradoxically repressing CYP11B2 while activating other steroidogenic genes [PMID:9139807, PMID:12193581, PMID:11932209]. Loss-of-function mutations cause corticosterone methyloxidase deficiency (types I and II), while chimeric CYP11B1/CYP11B2 genes arising from unequal crossing-over cause glucocorticoid-remediable aldosteronism [PMID:1594605, PMID:1303253].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of CYP11B2 as a second 11β-hydroxylase gene with divergent promoter architecture established that aldosterone biosynthesis could be genetically separable from cortisol production.\",\n      \"evidence\": \"Genomic cloning and sequencing of the human CYP11B locus revealed two nine-exon genes sharing 93% protein identity but with divergent 5′-flanking regions.\",\n      \"pmids\": [\"2592361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CYP11B2 transcripts were not detectable in normal adrenal at time of cloning\", \"enzymatic activity not yet assigned to the CYP11B2 product\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Functional reconstitution answered whether CYP11B2 encodes a distinct enzyme: its product catalyzes the complete conversion of deoxycorticosterone to aldosterone, while CYP11B1 cannot, establishing CYP11B2 as aldosterone synthase.\",\n      \"evidence\": \"cDNA expression in COS-7 and COS-1 cells with steroid product analysis demonstrated 11β-hydroxylase, 18-hydroxylase, and 18-oxidase activities for CYP11B2 but only 11β-hydroxylase for CYP11B1.\",\n      \"pmids\": [\"2256920\", \"1775135\", \"1741400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis for 18-oxidase specificity not determined\", \"electron transfer partners not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Genetic studies resolved the molecular basis of two Mendelian disorders: loss-of-function CYP11B2 mutations (R181W, V386A) cause corticosterone methyloxidase II deficiency, while chimeric CYP11B1/CYP11B2 genes from unequal crossing-over cause glucocorticoid-remediable aldosteronism, mapping disease-critical 18-oxidase determinants to the 3′ coding region.\",\n      \"evidence\": \"Patient sequencing, exon-swap constructs expressed in cultured cells, and Southern blot/PCR of chimeric genes across 12 kindreds.\",\n      \"pmids\": [\"1594605\", \"1346492\", \"1518866\", \"1303253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"genotype-phenotype discordance (CMO-I vs CMO-II) not fully explained by in vitro activity\", \"additional unidentified mutations or modifiers suggested by some pedigrees\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Promoter dissection identified the cis-regulatory logic of CYP11B2: a CRE-like element at −71/−64 binding CREB/ATF factors and an SF-1/COUP-TF element at −129/−114 are both required for basal activity and agonist (angiotensin II, K⁺, cAMP) induction.\",\n      \"evidence\": \"Deletion/mutation reporter constructs, DNase I footprinting, and EMSA with H295R adrenocortical cell nuclear extracts.\",\n      \"pmids\": [\"9139807\", \"9584833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of trans-acting factors mediating agonist-specific responses not fully resolved\", \"role of distal enhancers (e.g., Alu elements) not yet explored\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The calcium/calmodulin-dependent kinase CaMKI was identified as the specific kinase transducing calcium signals to CYP11B2 transcription via the CRE element, while SF-1 was shown to paradoxically repress CYP11B2—making it unique among steroidogenic genes.\",\n      \"evidence\": \"Constitutively active CaMK isoform transfections with CYP11B2 reporter and CRE mutations in H295R cells; SF-1 co-transfection assays comparing CYP11B2 with CYP11B1/CYP11A1/CYP17 reporters.\",\n      \"pmids\": [\"12193581\", \"11932209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"downstream transcription factor phosphorylated by CaMKI not identified\", \"mechanism of SF-1 repression unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Site-directed mutagenesis of specific residues (I112, D147, V381, I384) mapped substrate access and individual catalytic steps (11β-hydroxylation, 18-hydroxylation, 18-oxidation) to discrete structural features, advancing understanding of how CYP11B2 differs from CYP11B1 at the atomic level.\",\n      \"evidence\": \"Mutant CYP11B2 and CYP11B1 proteins expressed in E. coli with in vitro steroid hydroxylation assays and homology modeling.\",\n      \"pmids\": [\"11856349\", \"9874258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no experimental 3D structure available at this time\", \"electron transfer coupling not structurally characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Crystal structures of CYP11B2 with substrate (deoxycorticosterone) and inhibitor (fadrozole) revealed the structural basis of 18-oxidase specificity: divergent I-helix residues near the O₂ activation site and H-helix egress-channel loops retain reaction intermediates, while low processivity limits aldosterone output.\",\n      \"evidence\": \"X-ray crystallography at atomic resolution combined with biochemical substrate conversion assays.\",\n      \"pmids\": [\"23322723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no structure of CYP11B2 bound to 18-hydroxycorticosterone intermediate\", \"dynamic conformational changes during catalytic cycle not captured\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Post-transcriptional regulation of CYP11B2 was established: miR-10b and later miR-193a-3p directly target the CYP11B2 3′-UTR, adding a layer of negative regulation beyond transcriptional control.\",\n      \"evidence\": \"Luciferase reporter assays with wild-type and mutant 3′-UTR constructs, miRNA overexpression/knockdown, and functional rescue in H295R cells.\",\n      \"pmids\": [\"24768260\", \"29665181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"physiological contexts triggering miR-10b or miR-193a-3p regulation of aldosterone in vivo not established\", \"relative contribution of miRNA versus transcriptional regulation to aldosterone output unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Chemical biology identified a covalent inhibition mechanism exploiting Cys450 and Ala320 unique to CYP11B2: atractylenolide-I is epoxidized and covalently modifies Cys450, disrupting heme interaction and selectively inactivating aldosterone synthase without affecting CYP11B1.\",\n      \"evidence\": \"Activity-based protein profiling, molecular docking, mutagenesis, and cell-based aldosterone/cortisol assays with in vivo hyperaldosteronism model.\",\n      \"pmids\": [\"35127376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"co-crystal structure of covalent adduct not obtained\", \"pharmacokinetics and selectivity in humans unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Epigenetic regulation was defined: CYP11B2 promoter DNA methylation recruits MeCP2 and reduces CREB1/NGFIB binding, while physiological stimuli (low salt, angiotensin II, K⁺) induce promoter hypomethylation, linking environmental signals to epigenetic derepression.\",\n      \"evidence\": \"DNA methylation arrays, bisulfite sequencing, EMSA, and reporter assays in adrenal tissue and cell lines.\",\n      \"pmids\": [\"36982850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"identity of demethylase(s) mediating stimulus-dependent hypomethylation unknown\", \"relative importance of methylation versus transcription factor availability in vivo not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural dynamics of CYP11B2 during the multi-step catalytic cycle—particularly how intermediates (corticosterone, 18-hydroxycorticosterone) are retained or released, and how electron transfer from adrenodoxin is coupled to each oxidation step—remain incompletely resolved at the structural level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no structures of intermediate-bound states\", \"cryo-EM or time-resolved crystallography of catalytic cycle not performed\", \"in vivo regulation of CYP11B2 processivity not characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [1, 2, 3, 6, 15, 19, 24, 25]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [20, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 2, 3, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 18, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CYP11B1\",\n      \"SF1\",\n      \"CREB1\",\n      \"ATF2\",\n      \"CAMK1\",\n      \"MECP2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}